Peroxisome proliferators-activated alpha agonist treatment ameliorates hepatic damage in rats with obstructive jaundice: an experimental study

Table 2 Change in histopathologic scores (mean ± SD)*

	Sham	BDL	BDL + vehicle	BDL + fenofibrate
Portal inflammation	0	3.2 ± 0.2^a	3.1 ± 0.7^a	2.0 ± 0.5^a,b,c
Interface hepatitis	0	1.8 ± 0.7^a	1.7 ± 0.9^a	1.3 ± 0.6^a,b,c
Confluent necrosis	0	2.2 ± 0.^a	2.1 ± 0.9^a	1.1 ± 0.2^a,b,c
Lobar necrosis	0	3.0 ± 0.9^a	2.9 ± 0.7^a	2.1 ± 0.8^a,b,c
Bile duct number/5 portal field	3.5 ± 1.3	18.9 ± 8.0^a	17.5 ± 7.1^a	23.2 ± 11.1^a,b,c

*Comparisons between groups were done by using Kruskal-Wallis test. Paired comparisons are done by using Mann-Whitney U test.
^a P < 0.01 versus sham group (Mann-Whitney U)
^b P < 0.01 as compared to BDL group (Mann-Whitney U)
^c P < 0.01 as compared to BDL + vehicle group (Mann-Whitney U)

ISSN: 1471-230X